TMDX as reported
TransMedics Group, Inc. reported $636M of revenue over the trailing twelve months, +30% on the year before. 11 reported series are charted on this page, each one as filed.
$636M
Revenue, trailing twelve months · to Q1 2026 · +30% against the twelve months before
- Net Income
- $172M
Net Income · +251% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $151M
Free Cash Flow · −339% year on year · trailing twelve months to Q1 2026
- Op Margin
- 15%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $636M | +30% | Q1 2026 |
| Net Income | $172M | +251% | Q1 2026 |
| EPS | $4.37 | +219% | Q1 2026 |
| Gross Margin | 59% | n/a | Q1 2026 |
| Op Margin | 15% | n/a | Q1 2026 |
| Net Margin | 27% | n/a | Q1 2026 |
| ROE | 31% | n/a | Q1 2026 |
| ROA | 12% | n/a | Q1 2026 |
| ROIC | −69% | n/a | Q1 2023 · 12 quarters behind |
| Free Cash Flow | $151M | −339% | Q1 2026 |
| P/E | 21.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
TransMedics Group, Inc. (TMDX) - Revenue & ProfitRevenue & ProfitTransMedics Group, Inc. (TMDX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com